E-MTAB-779
Ontology highlight
ABSTRACT:
PROVIDER: E-MTAB-779 | ExpressionAtlas | 2025-01-23
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-MTAB-779-analysis-methods.tsv | Tabular | |||
| E-MTAB-779-atlasExperimentSummary.Rdata | Rdata | |||
| E-MTAB-779-configuration.xml | Xml | |||
| E-MTAB-779-percentile-ranks.tsv | Tabular | |||
| E-MTAB-779.condensed-sdrf.tsv | Tabular |
Items per page: 5 1 - 5 of 89 |
Similar Datasets
Project description:Transcription profiling by array of human breast cancer mammospheres and breast tumors
2025-01-24 | E-GEOD-7515 | ExpressionAtlas
Project description:Transcription profiling of human pre-malignant breast cancer samples
2025-01-24 | E-GEOD-7377 | ExpressionAtlas
Project description:To investigate the pathogenesis of malignant phyllodes tumors of the breast, we used lncRNA+mRNA microarray expression profiling as a platform to investigate lncRNAs that play a key role in the malignant progression of phyllodes tumors of the breast.A total of 4 cases of breast fibroadenomas, 6 cases of benign phyllodes tumors and 6 cases of malignant phyllodes tumors were included. Fibroadenomas and benign phyllodes tumors were used as controls to screen out significantly differentially expressed lncrnas in malignant phyllodes tumors.
2024-06-20 | GSE235267 | GEO
Project description:Meningiomas are common brain tumors that are classified into three World Health Organization grades (Grade I: benign, Grade II: atypical and Grade III: malignant) and are molecularly ill-defined tumors. The purpose of this study was identify microRNA (miRNA) molecular signatures unique to the different grades of meningiomas correlating them to prognosis. We have used a miRNA expression microarray to show that meningiomas of all three grades fall into two main molecular groups designated “benign” and “malignant” meningiomas. While all typical meningiomas fall into the benign group and all anaplastic meningiomas fall into the malignant group, atypical meningiomas distribute into either one of these groups. We have identified a miRNA signature that distinguishes benign meningiomas from malignant meningiomas.
2011-01-02 | GSE19720 | GEO
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as M-bM-^@M-^\C-signaturesM-bM-^@M-^]) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers. Total RNA obtained from serous ovarian adenocarcinomas, adenomas and borderline tumors. Gene expression profiling using Illumina's HT12 v4 bead arrays. Application of ovarian cancer molecular subtypes and intrinsic breast cancer subtypes using nearest centroid classification. KRAS and BRAF mutation analyses in the malignant and borderline tumors.
2014-08-15 | E-GEOD-57477 | biostudies-arrayexpress
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as “C-signatures”) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers.
2014-08-15 | GSE57477 | GEO
Project description:Expression profiling of human DCIS and invasive ductal breast carcinoma
2025-01-24 | E-GEOD-21422 | ExpressionAtlas
Project description:Meningiomas are common brain tumors that are classified into three World Health Organization grades (Grade I: benign, Grade II: atypical and Grade III: malignant) and are molecularly ill-defined tumors. The purpose of this study was identify microRNA (miRNA) molecular signatures unique to the different grades of meningiomas correlating them to prognosis. We have used a miRNA expression microarray to show that meningiomas of all three grades fall into two main molecular groups designated “benign” and “malignant” meningiomas. While all typical meningiomas fall into the benign group and all anaplastic meningiomas fall into the malignant group, atypical meningiomas distribute into either one of these groups. We have identified a miRNA signature that distinguishes benign meningiomas from malignant meningiomas. We studied the gene expression profiles of 340 mammalian miRNAs in 37 primary meningioma tumors by means of DNA microarrays.
2011-01-02 | E-GEOD-19720 | biostudies-arrayexpress
Project description:Exosomes are a subset of extracellular vesicles shuttling proteins, RNA, DNA and lipids crucial for cell–to–cell communication. Recent findings highlighted that exosomes, by virtue of their cargo, may also contribute to breast tumor growth and dissemination of metastasis. Indeed, these vesicles are gaining great interest as non-invasive cancer biomarkers. However, little is known on exosome biological and physical properties from breast malignant lesions and even less by non–malignant lesions such as breast fibroadenoma. The latter, being a non-malignant lesion, is clinically managed by conservative approaches. However, the molecular features of fibroadenoma are still largely unknown. In this pilot study, we attempt to purify and explore the proteomic profiling of breast benign and tumor exosomes from breast fibroadenoma, HER2+ and triple negative patient tumors as well from continuous cell lines by combining experimental and semi-quantitative approaches (BT-549, MCF10-A and MDA-MB-231). Interestingly, proteome-wide analyses showed 49 common proteins across breast fibroadenoma, HER2+, triple-negative malignant lesions and model cell exosomes. This is the first feasibility study evaluating physicochemical composition and proteome of extracellular vesicles from breast benign, malignant primary cells and immortalized cells. Our preliminary results may hold promises for freshly isolated primary cells protein identification with possible implications in breast cancer precision medicine.
2022-05-31 | PXD027197 | Pride
Project description:Quantification of Proteome heterogeneity in benign and malignant prostate tissues
2022-01-26 | E-PROT-66 | ExpressionAtlas